Policy & Regulation
Galderma secures Chinese approval for Relfydess to treat frown lines
23 October 2026 - Dermatology company Galderma (SIX:GALD) said on Friday that it has received approval from China's National Medical Products Administration for Relfydess (relabotulinumtoxinA) to...
Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease
23 October 2026 - RNAi (RNA interference) therapeutics company Alnylam Pharmaceuticals Inc (Nasdaq:ALNY) on Friday reported positive initial Phase 1b clinical trial results for brezosiran, an investig...
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
23 October 2026 - Zai Lab Limited (NASDAQ:ZLAB) (HKEX:9688), a research-based, commercial-stage biopharmaceutical company based in China and the United States, on Friday reported promising initial res...
Labcorp, Charles River and FDA collaborate on advancing preclinical methods for evaluating drug abuse potential
23 October 2026 - Laboratory services provider Labcorp (NYSE:LH) announced on Thursday a collaboration with the US Food and Drug Administration (FDA) and pharmaceutical research services provider Char...
HUYABIO International reports positive Phase 3 trial results for HBI-8000 and nivolumab combination
23 October 2026 - Biopharmaceutical company HUYABIO International announced on Thursday that oral HBI-8000 in combination with intravenous nivolumab reduced the risk of disease progression or death by...
Harbour BioMed's batoclimab injection receives Chinese regulatory approval to treat generalised myasthenia gravis
23 October 2026 - Chinese biopharmaceutical company Harbour BioMed (HKEX:02142) announced on Thursday that China's National Medical Products Administration (NMPA) has approved the Biologics Licen...